Catalyst supports innovations across all verticals, spanning the healthcare spectrum.


From century-old diseases to COVID-19, health systems, doctors, and patients around the globe demand new diagnostic approaches to address complex health conditions.  Catalyst candidates in diagnostics are harnessing groundbreaking innovations, such as artificial intelligence, machine learning, and predictive analytics to transform diagnostic assessments and remote health testing capabilities. See SEED or SnapDx as examples.

Digital Health

The convergence of clinical care, information science, and patientfacing technology is transforming how patients and their clinicians manage their health. Stanford Medicine, located in the heart of Silicon Valley, plays a leading role in the ongoing digital health revolution. Catalyst can provide digital health innovations with capital, healthcare system access and validation, and partnerships needed to propel a project’s success. Catalyst candidates in digital health span the gamut, from telehealth solutions, to wearables, to machine learning / AI, and beyond. See TrueImage, PocketRn, and VIVA as examples.

Stanford University Hospital Euan Ashley and his team in a testing lab in Palo Alto, California, Friday, May 19, 2017.  (Photo by Paul Sakuma Photography)

Medical Technology

Medical Technology includes hardware, devices, or instruments used for the diagnosis, mitigation, or treatment of a disease. Catalyst can provide medtech innovations with capital, expertise in design and prototyping, healthcare system pre-clinical and clinical access and validation, regulatory and reimbursement pathway consultation, and market access and business model development. We work in close collaboration with the Stanford Byers Center for Biodesign, world leaders in teaching the art and science of med-tech innovation. See Cardinal Robotics as one Catalyst example.


Developing successful therapeutic products takes many years and poses significant challenges and risks. Catalyst supports innovators with early proof of concept stage therapeutic solutions to propel them to IND readiness, and beyond. Catalyst partners and builds upon Stanford’s broad network to leverage essential resources at partner institutes like the Innovative Medicines Accelerator, Stanford ChEM-H, Stanford Bio-X, and the Wu Tsai Neurosciences Institute. See Hymecromone as one Catalyst example.

Researcher Kevin Wang in lab at Stanford University in Palo Alto, California, Monday, June 25, 2018.  He is holding a flask of cells that have been engineered to produce the Regina protein, a mammalian protein similar in structure to the active component of honeybee royal jelly.(Photography by Paul Sakuma Photography)